Cargando…

Lambert-Eaton Myasthenic syndrome: early diagnosis is key

Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiological and laboratory features. There are two forms of LEMS. The paraneoplastic (P-LEMS) form is associated with a malignant tumor that is most...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanovski, Trajche, Miralles, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524763/
https://www.ncbi.nlm.nih.gov/pubmed/31191084
http://dx.doi.org/10.2147/DNND.S192588
_version_ 1783419609134661632
author Ivanovski, Trajche
Miralles, Francesc
author_facet Ivanovski, Trajche
Miralles, Francesc
author_sort Ivanovski, Trajche
collection PubMed
description Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiological and laboratory features. There are two forms of LEMS. The paraneoplastic (P-LEMS) form is associated with a malignant tumor that is most frequently a small cell lung carcinoma (SCLC), and the autoimmune (A-LEMS) form is often related to other dysimmune diseases. Approximately 90% of LEMS patients present antibodies against presynaptic membrane P/Q-type voltage-gated calcium channels (VGCC). These antibodies are directly implicated in the pathophysiology of the disorder, provoke reduced acetylcholine (ACh) at the nerve terminal and consequently lead to muscle weakness. LEMS is clinically characterized by proximal muscle weakness, autonomic dysfunction and areflexia. In clinically suspected cases, diagnoses are confirmed by serological and electrodiagnostic tests. The detection of P/Q-type VGCC antibodies is supportive when there is clinical suspicion but should be carefully interpreted in the absence of characteristic clinical or electrodiagnostic features. Typical electrodiagnostic findings (ie, reduced compound motor action potentials (CMAPs), significant decrements in the responses to low frequency stimulation and incremental responses after brief exercise or high-frequency stimulation) reflect the existence of a presynaptic transmission defect and are key confirmatory criteria. Diagnosis requires a high level of awareness and necessitates the initiation of a prompt screening and surveillance process to detect and treat malignant tumors. In clinically affected patients without cancer and after cancer treatment, symptomatic treatment with 3,4-diaminopyridine or immunosuppressive agents can significantly improve neurologic symptoms and the quality of life. We present a detailed review of LEMS with special emphasis on the pathophysiological mechanisms, clinical manifestation and diagnostic procedure.
format Online
Article
Text
id pubmed-6524763
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65247632019-06-12 Lambert-Eaton Myasthenic syndrome: early diagnosis is key Ivanovski, Trajche Miralles, Francesc Degener Neurol Neuromuscul Dis Review Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiological and laboratory features. There are two forms of LEMS. The paraneoplastic (P-LEMS) form is associated with a malignant tumor that is most frequently a small cell lung carcinoma (SCLC), and the autoimmune (A-LEMS) form is often related to other dysimmune diseases. Approximately 90% of LEMS patients present antibodies against presynaptic membrane P/Q-type voltage-gated calcium channels (VGCC). These antibodies are directly implicated in the pathophysiology of the disorder, provoke reduced acetylcholine (ACh) at the nerve terminal and consequently lead to muscle weakness. LEMS is clinically characterized by proximal muscle weakness, autonomic dysfunction and areflexia. In clinically suspected cases, diagnoses are confirmed by serological and electrodiagnostic tests. The detection of P/Q-type VGCC antibodies is supportive when there is clinical suspicion but should be carefully interpreted in the absence of characteristic clinical or electrodiagnostic features. Typical electrodiagnostic findings (ie, reduced compound motor action potentials (CMAPs), significant decrements in the responses to low frequency stimulation and incremental responses after brief exercise or high-frequency stimulation) reflect the existence of a presynaptic transmission defect and are key confirmatory criteria. Diagnosis requires a high level of awareness and necessitates the initiation of a prompt screening and surveillance process to detect and treat malignant tumors. In clinically affected patients without cancer and after cancer treatment, symptomatic treatment with 3,4-diaminopyridine or immunosuppressive agents can significantly improve neurologic symptoms and the quality of life. We present a detailed review of LEMS with special emphasis on the pathophysiological mechanisms, clinical manifestation and diagnostic procedure. Dove 2019-05-13 /pmc/articles/PMC6524763/ /pubmed/31191084 http://dx.doi.org/10.2147/DNND.S192588 Text en © 2019 Ivanovski and Miralles. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Ivanovski, Trajche
Miralles, Francesc
Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title_full Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title_fullStr Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title_full_unstemmed Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title_short Lambert-Eaton Myasthenic syndrome: early diagnosis is key
title_sort lambert-eaton myasthenic syndrome: early diagnosis is key
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524763/
https://www.ncbi.nlm.nih.gov/pubmed/31191084
http://dx.doi.org/10.2147/DNND.S192588
work_keys_str_mv AT ivanovskitrajche lamberteatonmyasthenicsyndromeearlydiagnosisiskey
AT mirallesfrancesc lamberteatonmyasthenicsyndromeearlydiagnosisiskey